marbosan - bg 100.0 mg/ml
interchemie werken “de adelaar” b.v. - Марбофлоксацин - инжекционен разтвор - 100.0 mg/ml - говеда, свине
irbesan 150 mg film - coated tablets
Нобел Фарма ООД - Ирбесартан - 150 mg film - coated tablets
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Антинеопластични средства - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.